Oral administration of therapeutic proteins

Details Oral administration of therapeutic proteins Oral administration of therapeutic proteins

2000-03-29

2003-09-02

Minnifield, Nita (Department: 1645)

Drug, bio-affecting and body treating compositions

Antigen, epitope, or other immunospecific immunoeffector

C424S497000, C424S482000, C424S422000, C424S278100, C424S207100, C424S464000, C424S451000, C514S002600, C514S008100, C514S022000, C514S023000

Reexamination Certificate

active

06613332

ABSTRACT:

BACKGROUND OF THE INVENTION
Oral administration of any therapeutic agent is always problematic relative to administration by injection. Whereas administration by injection necessarily delivers the intact therapeutic agent into the body and where need be into the direct situs where it is required, with oral administration it is critical that the therapeutic agent pass through the digestive tract and be absorbed into the body without destruction of the therapeutic agent.
With smaller drugs such as aspirin and the like, this is not a critical problem. However, with larger molecules particularly proteins denaturization is a significant problem.
As discussed in the parent application, prior attempts to administer immunologically active proteins via oral ingestion had been unsuccessful. Likewise oral administration of any therapeutic protein has been generally unsuccessful.
With such therapy if the protein administered is a foreign protein, it will have an immunological effect activating the immune system. Whereas when the protein is a native protein such as insulin (whether derived from animal sources or produced from genetically modified microorganisms) the protein does not activate the immune system but rather establishes a concentration in the blood. Other such human proteins which are not recognized by the immune system as foreign would of course include human growth factor, transforming growth factor beta. There are of course a wide variety of therapeutic proteins which are not recognized as foreign by the immune system. Such natural proteins can have a wide variety of effects on the human body.
SUMMARY OF THE INVENTION
The present invention is premised on the realization that an orally administrable therapeutic proteins can be formed by microencapsulating the protein with a coating which is insoluble under acid conditions and resistant to proteolytic digestion. Such conditions are encountered in the mammalian stomach and part of the small intestines. Preventing exposure to acid and proteolytic digestion preserves antigenic structure of the protein and its ability to immunize.
The present invention is further premised on the realization that by microencapsulating the protein under totally aqueous conditions without employing any nonaqueous solvents, the structure of the protein remains intact.
More particularly, the present invention is premised on the realization that the therapeutic proteins should be coated with an acid stable coating under totally aqueous conditions so that they can pass through the stomach without being digested and then released intact into the small intestines where they can exert their therapeutic and/or immunological activity.
In a preferred embodiment, the enteric coating is a water emulsion of ethylacrylate methylacrylic acid copolymer, or hydroxypropyl methyl cellulose acetate succinate (HPMAS).


REFERENCES:
patent: 4016254 (1977-04-01), Seager et al.
patent: 4017647 (1977-04-01), Ohno et al.
patent: 4348384 (1982-09-01), Horikoshi et al.
patent: 4469677 (1984-09-01), Michael et al.
patent: 4507276 (1985-03-01), Tencza et al.
patent: 4642232 (1987-02-01), Yman et al.
patent: 4704295 (1987-11-01), Porter et al.
patent: 4728513 (1988-03-01), Ventouras
patent: 4774226 (1988-09-01), Lewenstein
patent: 4798844 (1989-01-01), Fujita et al.
patent: 4820627 (1989-04-01), McGeehan et al.
patent: 4874613 (1989-10-01), Hsiao et al.
patent: 4900557 (1990-02-01), Dell et al.
patent: 4920209 (1990-04-01), Davis et al.
patent: 4946945 (1990-08-01), Wojdani
patent: 4981693 (1991-01-01), Higashi et al.
patent: 4996058 (1991-02-01), Sinnreich et al.
patent: 5019384 (1991-05-01), Gefter et al.
patent: 5049390 (1991-09-01), Wojdani
patent: 5171568 (1992-12-01), Burke et al.
patent: 5202159 (1993-04-01), Chen et al.
patent: 5230888 (1993-07-01), Baltimore et al.
patent: 5236713 (1993-08-01), Wato et al.
patent: 5286493 (1994-02-01), Oshlack
patent: 5399347 (1995-03-01), Trentham et al.
patent: 5591433 (1997-01-01), Michael et al.
patent: 5609871 (1997-03-01), Michael et al.
patent: 5629001 (1997-05-01), Michael et al.
patent: 5783193 (1998-07-01), Michael et al.
patent: 6174529 (2001-01-01), Michael et al.
patent: 52792/90 (1989-03-01), None
patent: 1050358 (1979-03-01), None
patent: 1109796 (1981-09-01), None
patent: 2020654 (1991-01-01), None
patent: 0277741 (1988-08-01), None
patent: 319545 (1989-06-01), None
patent: 0603992 (2000-12-01), None
patent: 2723/849 (1994-08-01), None
patent: 01-287032 (1989-11-01), None
patent: WO90/04963 (1990-05-01), None
patent: WO92/06708 (1992-02-01), None
Adorini et al., Springer Semin Immunopathol vol. 14, 187-199, (1992).
Alonso, “Controlled Release of Tetanus Toxoid From Poly(Lactic/Glycolic Acid) Microspheres,” Proceed. Intern. Symp. Control. Rel. Bioact. Mater. Controlled Release Society, Inc., vol. 19 pp. 122-123 (1992).
Chanock et al. “Immunization by selective infection with Type 4 adenovirus grown in human diploid tissue culture,” JAMA 195(6):151-158 (1966).
Chemical Abstracts vol 96 p. 370 (1982).
Childers et al., Regional Immunology vol. 3(6), 289-296, 1990/1991).
Czerkinsky et al. “Induction and assessment of immunity at enteromucosal surfaces in humans: Implications for vaccine development” Clin. Infect. Dis. S106-113 (1993).
Davis et al., Microbiology, Third Edition, Chapter 67, p. 1270 (1980).
Eldridge, et al., “Controlled vaccine release in the gut-associated lymphoid tissues. I. Orally administered biodegradable microcapsules target to the Peyer's patches,” J. Controlled Release 11:205-214 (1990).
Engvall et al., The Journal of Immunology vol. 109(1), 129-135, (1972).
Excerpts fromStructure and Development of the Immune System, Chapter 2, pp. 29, 30-31.
Fox, Bio/Technology 12:128 (1994).
Fukumori, et al., Chem. Pharm. Bull. 36(12):4927-32 (1988).
Fukumori, et al., Chem. Pharm. Bull. 36(8):3070-78 (1988).
Gilligan, et al., Oral Vaccines: Design and Delivery, Int'l Journal of Pharmaceutics, vol. 75 pp. 1-24 (1991).
Haynes Science 260:1279-1286 (1993).
Lai “Design and evaluation of water based pseudo-latex enteinc coating systems,” Diss. Abs. Int. 49(10B):4254 (1985).
Langer, et al., Science 249:1527-1533 (1990).
Litwin et al, J. Allergy Clin. Immunol. 100:30-8 (1997).
Manganaro et al. “Oral immunization: Turning fantasy into reality,” Int. Arch Allergy Immunol. 103:223-233 (1994).
Michael, J. “The role of digestive enzymes in orally induced immune tolerance,” Immunogical Invest 18:1049-1054 (1989).
Moldoveanu et al. “Oral immunization with influenza virus in biodegradable micorspheres,” J. Infect. Dis. vol. 167 pp. 84-90 (1993).
Moldoveanu et al. Current Topics in Microbiol & Immunol. 146:91-99, (1989).
Mowat, Immunology Today vol. 8(3), 93-98, (1987).
Murray, et al., Aus. J. Hospital Pharm. 20(3):235-38 (1990).
Novak, et al., “Murine model for evaluation of protective immunity to influenza virus”.
O'Hagan et al. “Biodegradable Microparticles as Oral Vaccines,” Proceed. Intern. Symp. Control. Rel. Bioact. Mater., , Controlled Release Society, Inc., vol. 19 pp. 118-119 (1992).
O'Hagan et al., 1991, “Biodegradable microparticle as controlled release antigen delivery systems,” Immunology 73:239-242.
O'Hagan.Oral immunization and the common mucosal immune systemCRC Press, Inc. 1-24 (1994). Sandstrom et al, Drugs 34:372-390 (1987).
Sandstrom et al, Drugs 34:372-390 (1987).
Sayegh et al., Proc. Natl. Acad. Sci. USA vol. 89, 7762-7766 (1992).
Tamura et al. “Superior Cross-Protective Effect of Nasal Vaccination to Subcutaneous Inoculation with Influenza Hemagglutinin Vaccine,” Eur. J. Immunol. 22: 447-481 (1992).
Waldman et al. “Secretory Antibody following oral influenza immunization,” Am. J. Med. Sci. 292(6):367-71 (1986).
Waldman, Robert H., et al., “Age-Dependent Antibody Response in Mice and Humans Following Oral Influenza Immunization,” Journal of Clinical Immjnology, vol. 7, No. 4, pp. 327-332 (1987).
Wheeler et al. “Immunogenicity in guinea pigs and tolerance in grass” Int. Arch. Allergy Appl. Immunol. 83(4):354-8 (1987).
Wheeler et al., Int. Arch. Allergy Appl. Immunol. 83(4):354-8 (1987).

Affiliated with

Also associated with

Rating

Oral administration of therapeutic proteins does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Oral administration of therapeutic proteins, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Oral administration of therapeutic proteins will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3028503